In Vitro, Ex Vivo and In Vivo Evaluation of Microcontainers for Oral Delivery of Insulin

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

In Vitro, Ex Vivo and In Vivo Evaluation of Microcontainers for Oral Delivery of Insulin. / Jørgensen, Jacob Rune; Yu, Feiyang; Ramakrishnan, Venkatasubramanian; Nielsen, Line Hagner; Nielsen, Hanne Mørck; Boisen, Anja; Rades, Thomas; Mullertz, Anette .

In: Pharmaceutics, Vol. 12, No. 1, 48, 07.01.2020.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Jørgensen, JR, Yu, F, Ramakrishnan, V, Nielsen, LH, Nielsen, HM, Boisen, A, Rades, T & Mullertz, A 2020, 'In Vitro, Ex Vivo and In Vivo Evaluation of Microcontainers for Oral Delivery of Insulin', Pharmaceutics, vol. 12, no. 1, 48. https://doi.org/10.3390/pharmaceutics12010048

APA

Jørgensen, J. R., Yu, F., Ramakrishnan, V., Nielsen, L. H., Nielsen, H. M., Boisen, A., ... Mullertz, A. (2020). In Vitro, Ex Vivo and In Vivo Evaluation of Microcontainers for Oral Delivery of Insulin. Pharmaceutics, 12(1), [48]. https://doi.org/10.3390/pharmaceutics12010048

Vancouver

Jørgensen JR, Yu F, Ramakrishnan V, Nielsen LH, Nielsen HM, Boisen A et al. In Vitro, Ex Vivo and In Vivo Evaluation of Microcontainers for Oral Delivery of Insulin. Pharmaceutics. 2020 Jan 7;12(1). 48. https://doi.org/10.3390/pharmaceutics12010048

Author

Jørgensen, Jacob Rune ; Yu, Feiyang ; Ramakrishnan, Venkatasubramanian ; Nielsen, Line Hagner ; Nielsen, Hanne Mørck ; Boisen, Anja ; Rades, Thomas ; Mullertz, Anette . / In Vitro, Ex Vivo and In Vivo Evaluation of Microcontainers for Oral Delivery of Insulin. In: Pharmaceutics. 2020 ; Vol. 12, No. 1.

Bibtex

@article{89edc53eb26043c3969dcd01c77c4386,
title = "In Vitro, Ex Vivo and In Vivo Evaluation of Microcontainers for Oral Delivery of Insulin",
abstract = "Enhancing the oral bioavailability of peptides has received a lot of attention for decades but remains challenging, partly due to low intestinal membrane permeability. Combining a permeation enhancer (PE) with unidirectionally releasing microcontainers (MCs) has previously been shown to increase insulin permeation across Caco-2 cell monolayers. In the present work, this setup was further employed to compare three common PEs—sodium caprate (C10), sodium dodecyl sulfate (SDS), and lauroyl carnitine. The concept was also studied using porcine intestinal tissue with the inclusion of 70 kDa fluorescein isothiocyanate-dextran (FD70) as a pathogen marker. Moreover, a combined proteolysis and Caco-2 cell permeation setup was developed to investigate the effect of soybean trypsin inhibitor (STI) in the MCs. Lastly, in vivo performance of the MCs was tested in an oral gavage study in rats by monitoring blood glucose and insulin absorption. SDS proved to be the most potent PE without increasing the ex vivo uptake of FD70, while the implementation of STI further improved insulin permeation in the combined proteolysis Caco-2 cell setup. However, no insulin absorption in rats was observed upon oral gavage of MCs loaded with insulin, PE and STI. Post-mortem microscopic examination of their gastrointestinal tract indicated lack of intestinal retention and optimal orientation by the MCs, possibly precluding the potential advantage of unidirectional release.",
author = "J{\o}rgensen, {Jacob Rune} and Feiyang Yu and Venkatasubramanian Ramakrishnan and Nielsen, {Line Hagner} and Nielsen, {Hanne M{\o}rck} and Anja Boisen and Thomas Rades and Anette Mullertz",
year = "2020",
month = "1",
day = "7",
doi = "10.3390/pharmaceutics12010048",
language = "English",
volume = "12",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "MDPI AG",
number = "1",

}

RIS

TY - JOUR

T1 - In Vitro, Ex Vivo and In Vivo Evaluation of Microcontainers for Oral Delivery of Insulin

AU - Jørgensen, Jacob Rune

AU - Yu, Feiyang

AU - Ramakrishnan, Venkatasubramanian

AU - Nielsen, Line Hagner

AU - Nielsen, Hanne Mørck

AU - Boisen, Anja

AU - Rades, Thomas

AU - Mullertz, Anette

PY - 2020/1/7

Y1 - 2020/1/7

N2 - Enhancing the oral bioavailability of peptides has received a lot of attention for decades but remains challenging, partly due to low intestinal membrane permeability. Combining a permeation enhancer (PE) with unidirectionally releasing microcontainers (MCs) has previously been shown to increase insulin permeation across Caco-2 cell monolayers. In the present work, this setup was further employed to compare three common PEs—sodium caprate (C10), sodium dodecyl sulfate (SDS), and lauroyl carnitine. The concept was also studied using porcine intestinal tissue with the inclusion of 70 kDa fluorescein isothiocyanate-dextran (FD70) as a pathogen marker. Moreover, a combined proteolysis and Caco-2 cell permeation setup was developed to investigate the effect of soybean trypsin inhibitor (STI) in the MCs. Lastly, in vivo performance of the MCs was tested in an oral gavage study in rats by monitoring blood glucose and insulin absorption. SDS proved to be the most potent PE without increasing the ex vivo uptake of FD70, while the implementation of STI further improved insulin permeation in the combined proteolysis Caco-2 cell setup. However, no insulin absorption in rats was observed upon oral gavage of MCs loaded with insulin, PE and STI. Post-mortem microscopic examination of their gastrointestinal tract indicated lack of intestinal retention and optimal orientation by the MCs, possibly precluding the potential advantage of unidirectional release.

AB - Enhancing the oral bioavailability of peptides has received a lot of attention for decades but remains challenging, partly due to low intestinal membrane permeability. Combining a permeation enhancer (PE) with unidirectionally releasing microcontainers (MCs) has previously been shown to increase insulin permeation across Caco-2 cell monolayers. In the present work, this setup was further employed to compare three common PEs—sodium caprate (C10), sodium dodecyl sulfate (SDS), and lauroyl carnitine. The concept was also studied using porcine intestinal tissue with the inclusion of 70 kDa fluorescein isothiocyanate-dextran (FD70) as a pathogen marker. Moreover, a combined proteolysis and Caco-2 cell permeation setup was developed to investigate the effect of soybean trypsin inhibitor (STI) in the MCs. Lastly, in vivo performance of the MCs was tested in an oral gavage study in rats by monitoring blood glucose and insulin absorption. SDS proved to be the most potent PE without increasing the ex vivo uptake of FD70, while the implementation of STI further improved insulin permeation in the combined proteolysis Caco-2 cell setup. However, no insulin absorption in rats was observed upon oral gavage of MCs loaded with insulin, PE and STI. Post-mortem microscopic examination of their gastrointestinal tract indicated lack of intestinal retention and optimal orientation by the MCs, possibly precluding the potential advantage of unidirectional release.

U2 - 10.3390/pharmaceutics12010048

DO - 10.3390/pharmaceutics12010048

M3 - Journal article

C2 - 31936066

VL - 12

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 1

M1 - 48

ER -

ID: 234141186